Evidence map›Paper›PMID 31670340›Full record

ArticleNanoscale2019

Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.

Piyush K Jain, Justin H Lo, Santosh Rananaware, Marco Downing, Apekshya Panda, Michelle Tai, Srivatsan Raghavan, Heather E Fleming, Sangeeta N Bhatia

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Liposome-Based Carriers for CRISPR Genome Editing.International journal of molecular sciences · 2023
    Review
  6. Review
  7. New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  8. Article
  9. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  10. Review
  11. CRISPR: The Multidrug Resistance Endgame?Molecular biotechnology · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Piyush K JainDepartment of Chemical Engineering, University of Florida, Gainesville, FL 32611, USA and Marble Center for Cancer Nanomedicine, Institute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and UF Health Cancer Center, University of Florida, Gainesville, FL 32608. jainp@ufl.edu.ORCID http://orcid.org/0000-0001-7153-442X
Justin H LoMarble Center for Cancer Nanomedicine, Institute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Division of Hematology and Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID http://orcid.org/0000-0002-2646-2495
Santosh RananawareDepartment of Chemical Engineering, University of Florida, Gainesville, FL 32611, USA.ORCID http://orcid.org/0000-0001-8789-5799
Marco DowningDepartment of Chemical Engineering, University of Florida, Gainesville, FL 32611, USA.ORCID http://orcid.org/0000-0001-8045-7024
Apekshya PandaDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.ORCID http://orcid.org/0000-0002-8369-9835
Michelle TaiDepartment of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Srivatsan RaghavanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA and Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA.
Heather E FlemingMarble Center for Cancer Nanomedicine, Institute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID http://orcid.org/0000-0002-5286-3794
Sangeeta N BhatiaMarble Center for Cancer Nanomedicine, Institute for Medical Engineering & Science, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139, USA and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA and Howard Hughes Medical Institute, Cambridge, MA 02139, USA. sbhatia@mit.edu.ORCID http://orcid.org/0000-0002-1293-2097
Broad Institute · USMassachusetts Institute of Technology · USUniversity of Florida · USUniversity of Florida Health · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
The Development of Clinical Grade, Targeted Magnetic NanoparticlesU54CA151884 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2010 to 2014
$11.3M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014051NCI NIH HHS U54 CA151884
6 · The paper itself

Abstract

There is a critical need for the development of safe and efficient delivery technologies for CRISPR/Cas9 to advance translation of genome editing to the clinic. Non-viral methods that are simple, efficient, and completely based on biologically-derived materials could offer such potential. Here we report a simple and modular tandem peptide-based nanocomplex system with cell-targeting capacity that efficiently combines guide RNA (sgRNA) with Cas9 protein, and facilitates internalization of sgRNA/Cas9 ribonucleoprotein complexes to yield robust genome editing across multiple cell lines.

Indexed as

CRISPR-Cas SystemsGene EditingGene Transfer TechniquesHeLa CellsHumans

Identifiers

PMID31670340
PMCPMC7709491
OpenAlexW2982654391

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.